leadf
logo-loader
RNS
viewDechra Pharmaceutical

Dechra Pharm PLC - Director/PDMR Shareholding

RNS Number : 9431A
Dechra Pharmaceuticals PLC
02 October 2020
 



 

 

 

2 October 2020

 

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

 

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

 

 

 

Dechra Pharmaceuticals PLC announces that on 1 October 2020, Paul Sandland, Executive Director and PDMR exercised approved and unapproved options over ordinary shares of 1p each in the Company. The options were granted under the Dechra Pharmaceuticals Approved Option Scheme and Dechra Pharmaceuticals Unapproved Option Scheme as detailed below. The exercise of the options was subject to the achievement of performance conditions which were satisfied to the extent that the options vested at 100%. Paul Sandland sold 2,474 of the shares acquired, and retained the remaining 1,449 shares. 

 

Date of Grant

Scheme

Number of options exercised

Option Price

Number of shares sold

Sale Price

15 September 2015

Approved

923

£9.75

Nil

N/A

19 September 2016

Approved

526

£13.69

Nil

N/A

19 September 2016

Unapproved

2,474

£13.69

2,474

£32.23

 

Paul Sandland's total beneficial holding following these transactions is 6,518 ordinary shares which represents 0.006% of the total issued share capital.

 

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 

Notification of Dealing Forms

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Paul Sandland

 

2.

Reason for the notification

a)

Position/status

Director/PDMR

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

 

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

 

ISIN: GB0009633180

b)

Nature of the transaction

Exercise of options under the Company's Approved Option Scheme

 

c)

Price(s) and volumes(s)

Price(s)

£9.75

£13.69

Volume(s)

923

526

d)

Aggregated information

-    Aggregate volume

-    Price

-    Total

 

 

1,449

£11.18

£16,200.19

e)

Date of the transaction

2020.10.01

f)

Place of the transaction

Outside a trading venue

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Paul Sandland

 

2.

Reason for the notification

a)

Position/status

Director/PDMR

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

 

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

 

ISIN: GB0009633180

b)

Nature of the transaction

Exercise of options under the Company's Unapproved Option Scheme

 

c)

Price(s) and volumes(s)

Price(s)

£13.69

Volume(s)

2,474

d)

Aggregated information

-    Aggregate volume

-    Price

-    Total

 

 

2,474

£13.69

 

£33,869.06

e)

Date of the transaction

2020.10.01

f)

Place of the transaction

Outside a trading venue

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Paul Sandland

 

2.

Reason for the notification

a)

Position/status

Director/PDMR

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

 

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

 

ISIN: GB0009633180

b)

Nature of the transaction

Sale of shares obtained under the Company's Unapproved Share Option Scheme

 

c)

Price(s) and volumes(s)

Price(s)

£32.23

Volume(s)

2,474

d)

Aggregated information

-    Aggregate volume

-    Price

-    Total

 

2,474

 

£32.23

£79,737.02

e)

Date of the transaction

2020.10.01

f)

Place of the transaction

London Stock Exchange

 

 

 

For further information, please contact:

 

Melanie Hall, Company Secretary                          

Telephone number: 01606 814730

 

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKKBBKFBDKBKK

Quick facts: Dechra Pharmaceutical

Price: -

Market: LSE
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

7 min read